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To evaluate the antihyperglycemic eﬀect of ethyl acetate fraction of ethanol extract of Stereospermum suaveolens in streptozotocin-
(STZ-) induced diabetic rats by acute and subacute models. In this paper, various fractions of ethanol extract of Stereospermum
suaveolens were prepared and their eﬀects on blood glucose levels in STZ-induced diabetic rats were studied after a single oral
administration (200mg/kg). Administration of the ethyl acetate fraction at 200mg/kg once daily for 14 days to STZ-induced
diabetic rats was also carried out. The parameters such as the fasting blood glucose, hepatic glycogen content, and pancreatic
antioxidant levels were monitored. In the acute study, the ethyl acetate fraction is the most potent in reducing the fasting serum
glucose levels of the STZ-induced diabetic rats. The 14-day repeated oral administration of the ethyl acetate fraction signiﬁcantly
reduced the fasting blood glucose and pancreatic TBARS level and signiﬁcantly increased the liver glycogen, pancreatic superoxide
dismutase, and catalase activities as well as reduced glutathione levels. The histopathological studies during the subacute treatment
have been shown to ameliorate the STZ-induced histological damage of pancreas. This paper concludes that the ethyl acetate
fraction from ethanol extract of Stereospermum suaveolens possesses potent antihyperglycemic and antioxidant properties, thereby
substantiating the use of plant in the indigenous system of medicine.
1.Introduction
Diabetes mellitus is a chronic disorder in the metabolism
of carbohydrates, proteins, and fat due to absolute or
relative deﬁciency of insulin secretion with/without varying
the degree of insulin resistance [1]. In the recent past,
many antidiabetic agents are introduced, still the diabetes
and the related complications continue to be a major
medical problem, not only in developed countries but also
in developing countries. Medicinal plants used to treat
hyperglycemic conditions are of considerable interest for
ethnobotanical community as they are recognized to contain
valuable medicinal properties in diﬀerent parts of the plant,
and a number of plants have shown varying degree of
hypoglycemic and antihyperglycemic activity [2].
Stereospermum suaveolens (Roxb.) DC, family Bignon-
iaceae, commonly known as Padiri, is a large deciduous
tree found throughout the moist parts of India. Diﬀerent
parts of the plant have been used in Ayurvedic medicine to
treat various kinds of diseases. Traditionally, the decoction
of bark and root is used for the treatment of pain, fever,
inﬂammations, asthma, liver disorders, and as a diuretic
[3, 4]. The ﬂowers are mixed with honey and given orally,
for the control of hiccup [5]. In southern India, the bark
is used traditionally for the treatment of diabetes [3]. The
root extract is known to possess anticancer activity [3, 6].
The previous phytochemical studies reported the presence of
lapachol [7], sterekunthal B, stereochenols A and B [8, 9]i n
the bark, and scutellarein [10], stereolensin, dinatin (4,5,7-
trihydroxyl-6-methoxyﬂavon), and dinatin-7-glucuroniside
[11] in the leaves.
Earlier studies in our laboratory have reported the
antihyperglycemic and antioxidant activities of the crude
ethanol extract of Stereospermum suaveolens (EESS) bark
in experimental rats [12]. However, the antihyperglycemic
activity of the fractions of this plant has not been elucidated
yet, and there is a need to isolate the potent antidiabetic2 The Scientiﬁc World Journal
fraction from ethanol extract of Stereospermum suaveolens
to obtain novel prototypes to manage diabetes mellitus.
Hence, in the present work, we made an attempt to evaluate
the antihyperglycemic in addition to pancreatic antioxidant
eﬀects of ethyl acetate fraction of EESS in streptozotocin-
induced diabetic rats by acute and subacute models.
2.MaterialsandMethods
2.1. Chemicals. Streptozotocin and other chemicals were
purchased from SISCO Research Laboratory, India. Gliben-
clamide was obtained from Prudence Pharma Chem,
Ankeshwara, Gujarat. The used solvents and chemicals were
analytical grade.
2.2. Plant Material. The plant was identiﬁed and authen-
ticated by the Tropical Botanical Garden and Research
Institute,Palode,Thiruvananthapuramdistrict,Kerala,India
and a voucher specimen (TBS-1) has been deposited in our
laboratory for further reference. The bark of Stereospermum
suaveolens (Roxb.) DC was collected during October 2006
from Palode forest, Thiruvananthapuram district, Kerala,
India. The bark of the plant was dried under shade and
powdered with a mechanical grinder. The powdered plant
material was then passed though sieve no. 40 and stored in
an air tight container for future use.
2.3.PreparationoftheCrudePlantExtractandFractions. The
shade dried coarse powder bark of Stereospermum suaveolens
(500g) was packed in the soxhlet extraction apparatus and
extracted with 1.5 litre of 95% ethanol at temperature of 40–
50◦C for 72h. The extract was ﬁltered and then concentrated
to dryness in a rotary evaporator under reduced pressure
at temperature of 40◦C. Then the crude ethanol extract of
Stereospermum suaveolens (100g) was dissolved in distilled
water (500mL) and fractionated with pet ether, chloroform,
and ethyl acetate.
The resultant black color residues were stored in a
dessicator for use in subsequent experiments and considered
as the crude ethanol extract and fractions. The yield of
the crude ethanol extract, pet ether, chloroform, ethyl
acetate, and aqueous fractions were 25, 10, 7.16, 16.52, and
20.45%w/w, respectively. Weighed amount of fractions were
suspended in 5% DMSO in normal saline prior to oral
administration.
2.4. Animals. Male Wistar albino rats (weighing 150–200g)
and male Swiss albino mice (20–25g) were purchased from
M/S-Ghosh Enterprises, Kolkata, India. The animals were
randomly grouped (n = 6) and housed in polyacrylic
cages (38×23×10cm) and maintained under standard
laboratory conditions (25 ± 2◦C) with dark and light cycle
(14/10h). They were allowed free access to standard dry
pellet diet (Hindustan Lever, Kolkata, India) and water
adlibitum.Theratswereacclimatizedtolaboratorycondition
for 1 week before commencement of experiment. Ethical
clearance was obtained from Jadavpur University Animals
Ethical Committee for using animals in the present study.
2.5. Acute Oral Toxicity Study. An acute oral toxicity study
was performed as per OECD-423 guidelines [13]. Male Swiss
albino mice (20–25g) were randomly distributed to twenty-
fourgroupsofthreeeach.Theanimalswerefastedovernight,
and the fractions were administered orally at doses of 100,
200, 400, 800, 1600, and 3200mg/kg body weight. The
animals were closely observed for the ﬁrst 24h for any toxic
symptoms and for 72h for any mortality.
3.ExperimentalDesign
3.1. Induction of Experimental Diabetes. Rats were fasted for
16h before the induction of diabetes with STZ. A freshly
prepared solution of STZ (50mg/kg) in 0.1M cold citrate
buﬀer, pH:4.5, were injected intraperitoneally in a volume
of 1mL/kg [14], and the control rats were injected with
citrate buﬀer alone. In order to control the hypoglycemia
during the ﬁrst day after the STZ administration, diabetic
rats were given 5% glucose solution orally. Hyperglycemia
was conﬁrmed by the elevated fasting glucose levels in
blood, determined at 48h and then on day 6 after injection.
Rats with diabetes exhibiting fasting blood glucose levels
in the range of 260–325mg/100mL were selected for the
studies, and blood glucose levels were measured by reﬂective
glucometer (Accu-chek) using the glucose oxidase method.
3.2. Acute Antihyperglycemic Study [15]. The rats were fasted
for 16h, divided into seven groups of six each, and treated
as follows: Group I, nondiabetic control, was given 5%
DMSO in normal saline orally at a dose of 5mL/kg. Group
II, STZ-diabetic control, received 5% DMSO in normal
saline (5mL/kg) orally. Groups III–VI, STZ-diabetic rats,
were treated with pet ether, chloroform, ethyl acetate, and
aqueous fractions (200mg/kg, orally), respectively. Group
VII, STZ-diabetic rats, was administered with standard drug
Glibenclamide at a dose of 0.5mg/kg orally. Blood samples
were taken from the tail vein at 0, 0.5, 1, 2, 4, and 5h after
theoraladministration,andfastingbloodglucoselevelswere
determined.
3.3. Subacute Antihyperglycemic Study (14 Days). Rats were
fasted for 16h and divided into four groups of six each
[16]. Group I, nondiabetic control, were given 5% DMSO
in normal saline orally at a dose of 5mL/kg. Group II,
STZ-diabetic control, received 5% DMSO in normal saline
at a dose of 5mL/kg orally. Group III, STZ-diabetic rats,
was treated with ethyl acetate fraction orally at a dose of
200mg/kg. Group IV STZ-diabetic rats were administered
with standard drug Glibenclamide at a dose of 0.5mg/kg
orally. The treatment was continued once daily for 14 days.
Fasting blood glucose level of each animal was determined
on days 1, 4, 7, 10, and 15 after the initiation of treatment.
The body weights of animals were also monitored on the
same days. On the 15th day, all the rats were sacriﬁced
by euthanasia and the liver and pancreas were excised
immediately and washed with ice cold saline solution.The Scientiﬁc World Journal 3
Table 1:EﬀectofvariousfractionofethanolextractofStereospermumsuaveolensonglucoselevelbyacutetreatmentinSTZ-induceddiabetic
rat.
Groups 0h 1/2h 1h 2h 4h 5h
Normal (5%
DMSO in 0.9%
NaCl, 5mL /kg )
84.16 ± 2.34 85.00 ± 2.68 87.73 ± 2.21 90.23 ± 2.05 89.13 ± 2.34 83.83 ± 2.44
STZ-induced
diabetic control
(40mg/kg)
294.65 ± 1.86 a,∗∗ 300.21 ± 3.57a,∗∗ 302.25 ± 6.10a,∗∗ 298.16 ± 5.31a,∗∗ 299.56 ± 6.24a,∗∗ 305.16 ± 4.82a,∗∗
STZ+ Pet ether
fraction
(200mg/kg)
284.04 ± 1.82 280.14 ± 5.76 265.16 ± 6.28b,∗ 256.53 ± 6.72b,∗∗ 248.83 ± 6.42b,∗ 234.71 ± 5.67b,∗∗
STZ +
Chloroform
fraction
(200mg/kg)
267.24 ± 1.46 262.63 ± 1.45 258.84 ± 2.18 254.5 ± 2.14 253.49 ± 2.81 261.24 ± 3.81
STZ + Ethyl
acetate fraction
(200mg/kg)
264.81 ± 1.96 241.16 ± 4.54 229.23 ± 6.14b,∗∗ 212.38 ± 6.51b,∗∗ 197.67 ± 7.68b,∗∗ 187.28 ± 6.436b,∗∗
STZ + Aqueous
fraction
(200mg/kg)
286.90 ± 2.31 285.09 ± 3.81 281.84 ± 2.18 279.30 ± 2.72 272.65 ± 2.73 279.50 ± 3.73
STZ +
Glibenclamide
(0.5mg/kg)
286.50 ± 6.35 255.50 ± 8.08b,∗∗ 224.83 ± 7.18b,∗∗ 162.00 ± 7.81b,∗∗ 162.00 ± 7.81b,∗∗ 111.50 ± 7.13b,∗∗
Values are given as mean ± SEM, 6 rats in each group,
a,∗∗P<0.001 as compared to normal control group,
b,∗P<0.05, ∗∗P<0.001, when compared with STZ-treated control group.
3.4. Estimation of Liver Glycogen Content. The glycogen
content was determined from the liver expressed as mg/g of
liver tissue [17].
3.5. Estimation of Antioxidant Assays. After the determina-
tion of blood glucose level, the rats were sacriﬁced and
pancreas was excised, rinsed in ice-cold normal saline (pH:
7.4),blotteddryandweighed.A10%w/vofhomogenatewas
prepared in 1.15% KCl and processed for the estimation of
lipid peroxidation [18], reduced glutathione content (GSH)
[19] (Ellman, 1959), superoxide dismutase (SOD) [20],
catalase (CAT) [21], and total proteins [22].
3.6. Histopathological Study. T h era t sw e r es a c ri ﬁ c e do n1 5 t h
day after the determination of fasting blood glucose level,
and the pancreas tissues were harvested. The fragments from
the tissues were ﬁxed in 10% neutral formalin solution,
embedded in paraﬃn, and then, stained with hematoxylin
(H) and eosin (E).
3.7. Statistical Analysis. The experimental data were
expressed as mean±SEM. The data were analyzed using
ANOVA and Dunett’s test. The results were considered
statistically signiﬁcant if P<0.05.
4. Results
4.1. Acute Oral Toxicity Study. The pet ether, chloroform,
ethyl acetate, and aqueous fractions of ethanol extract of
Stereospermum suaveolens (EESS) did not show any mor-
tality and toxic manifestations upto the dose of 3200mg/kg.
b.w. Further dosing was not performed to estimate the LD50
(lethal dose) value. According to the OECD guidelines for
the acute toxicity, an LD50 dose of 2000mg/kg and above is
categorized as unclassiﬁed and hence the drug is found to be
safe. Based on the acute toxicity studies, the dose 200mg/kg
of the fractions has been selected as the therapeutic dose.
4.2. Acute Antihyperglycemic Study. The eﬀects of the pet
ether, chloroform, ethyl acetate, and aqueous fractions of
EESS on the blood glucose in STZ-induced diabetic rats
are depicted in Table 1. The blood glucose levels were
signiﬁcantly (P<0.001) elevated in diabetic control
rats as compared to nondiabetic control rats. Oral acute
administration of pet ether (P<0.05, P<0.001) and ethyl
acetate(P<0.001)fractionsofEESSatthedoseof200mg/kg
signiﬁcantly lowered the elevated blood glucose level in
STZ-induced diabetic rats as compared to diabetic control
rats, while chloroform and aqueous fractions were devoid
of antihyperglycemic activity. The ethyl acetate fraction
produced more potent eﬀects than pet ether fraction in acute
antihyperglycemic model.
4.3. Subacute Antihyperglycemic Study
4.3.1. Eﬀect on Blood Glucose Levels. The eﬀect of the ethyl
acetate fraction of EESS on the fasting blood glucose levels
in STZ-induced diabetic rats is shown in Table 2.T r e a t m e n t
of normal control rats with vehicle (5% DMSO) alone does4 The Scientiﬁc World Journal
Table 2: Eﬀe c to fe t h y la c e t a t ef r a c t i o no fstereospermum suaveolens on glucose level in STZ-induced diabetic rats.
Groups
Serum glucose levels (mg/dL)
1day 5thday 7thday 10thday 15thday
Normal
(5% DMSO in 0.9% NaCl, 5mL/kg) 85.64 ± 1.99 85.84 ± 2.18 87.84 ± 2.18 91.64 ± 1.36 86.60 ± 1.91
STZ-induced diabetic control
(40mg/kg) 290.65 ±1.86a,# 294.80 ±2.35a,# 294.84 ±2.18a,# 299.2 ±1.46a,# 293.40 ±2.42a,#
STZ + Ethyl acetate fraction
(200mg/kg) 264.81 ±1.96b,∗ 247.86 ±1.86b,∗∗ 211.84 ±2.18 b,∗∗ 187.6 ±2.18b,∗∗ 129.42 ±1.9b,∗∗
STZ+ Glibenclamide
(0.5mg/kg) 286.50 ± 6.35 173.50 ± 6.35b,∗ 141.72 ± 6.26b,∗ 126.21 ± 6.61b,∗ 115 ± 6.11b,∗
Values are given as mean ± SEM, 6 rats in each group,
a,#P<0.001 as compared to normal control group,
b,∗P<0.05, ∗∗P<0.001, when compared with STZ-treated control group.
Table 3: Eﬀect of ethyl acetate fraction of Stereospermum suaveolens on body weight in STZ-induced diabetic rats.
Groups
Body weight (g)
1st day 4th day 7th day 10th day 15th day
Normal (5% DMSO in 0.9% NaCl, 5mL/kg) 185.73 ±1.96 185.86 ±1.32 196.00 ±3.37 193.72 ±3.24 197.26 ±2.06
STZ-induced diabetic control (40mg/kg) 181.25 ±2.61 171.63 ±2.70a,# 164.81 ±3.73a,# 154.53 ±2.74a,# 154.13 ±1.86a,#
STZ + Ethyl acetate fraction (200mg/kg) 182.60 ±3.24 184.57±0.64b,∗∗ 189.12±2.38b,∗∗ 191.62±2.29b,∗∗ 194.57±1.25b,∗∗
STZ + Glibenclamide (0.5mg/kg) 184.06 ±3.22 172.50 ±0.84 169.13 ±2.40 164.26 ±2.21 159.56 ±1.45
Values are mean ± SEM, 6 rats in each group,
a,#P<0.001 as compared to normal control group,
b,∗∗P<0.001, when compared with STZ-treated control group.
not aﬀect the normal glucose concentration throughout the
study.Repeatedoraladministrationwithadoseof200mg/kg
of the ethyl acetate fraction of EESS to STZ-induced diabetic
rats for 14days signiﬁcantly (P<0.001) reduced the elevated
f a s t i n gb l o o dg l u c o s el e v e l sa td a y s1 ,4 ,7 ,1 0 ,a n d1 5a f t e r
initiation of treatment, when compared to diabetic control
rats. The eﬀect of ethyl acetate fraction is comparable to that
of glibenclamide.
4.3.2. Eﬀect of Fractions on Body Weight. The eﬀect of the
ethyl acetate fraction on body weight in the STZ-induced
diabetic rats is given in Table 3. The body weight was slightly
increased in the normal control rats (in 14days period)
compared to initial body weight, whereas in the diabetic
control rats, there was a signiﬁcant decrease in the body
weight over the same period. The ethyl acetate fraction
of EESS-treated diabetic rats gained signiﬁcant weight but
the increase remained lesser than the nondiabetic controls.
Glibenclamide (0.5mg/kg) treatment signiﬁcantly reduced
the body weight of diabetic rats.
4.3.3. Eﬀect of Hepatic Glycogen Content. The liver glycogen
content was signiﬁcantly decreased in STZ-induced diabetic
rats as compared to nondiabetic rats, and the result is shown
in Table 4. Treatment with ethyl acetate fraction of EESS
signiﬁcantly (P<0.001) increased the liver glycogen levels
in STZ-induced diabetic rats.
4.4. Eﬀects on Pancreatic In Vivo Antioxidant Activities
4.4.1. Lipid Peroxidation. STZ-induced diabetic control rats
show an increased TBARS (thiobarbituric acid reactive
substances) level in pancreas (Table 4) as compared to non-
diabeticrats.However,ethylacetatefractionwassigniﬁcantly
(P<0.001) decreased TBARS as compared to respective
diabetic control rats.
4.4.2. Reduced Glutathione Content. The total GSH content
decreased in STZ-induced diabetic rats as compared to
nondiabetic rats. Treatment with ethyl acetate fraction were
signiﬁcantly (P<0.001) increased total GSH in pancreas
when compared to STZ-induced diabetic control rats and is
shown in Table 4.
4.4.3. Superoxide Dismutase and Catalase. SOD and catalase
(CAT) activities in the STZ-induced diabetic rats weresignif-
icantly (P<0.001) decreased in pancreas. Administration of
ethyl acetate fraction signiﬁcantly (P<0.001) increased the
SOD and CAT activities compared to STZ-induced diabetic
control rats and is shown in Table 4.
4.4.4. Histopathological Studies of Pancreas. Histopatholog-
ical section of nondiabetic control pancreas (Figure 1)
showing normal islets with clusters of purple-stained β-cells.
Figure 2 presents the section of diabetic pancreas showing
atrophyofβ-cellsandvacuolardegenerativechangesinislets,
andmildinﬁltrationofinﬂammatorycells.ItischaracterizedThe Scientiﬁc World Journal 5
Table 4: Eﬀect of ethyl acetate fraction of Stereospermum suaveolens on pancreatic lipid peroxidation, glutathione, and antioxidants in
STZ-induced diabetic rats.
Groups
Lipid peroxidation
(nmol of MDA/mg
protein)
Glutathione (μM/gm
protein)
Superoxide
dismutase
(IU/mg protein)
Catalase (nmol
of H2O2 decom-
posed/min/mg
protein)
Liver glycogen
(mg/gm of liver)
Normal (5% DMSO in 0.9%
NaCl, 5mL/kg) 11.13 ±0.56 49.28 ±1.26 26.42 ±0.68 56.26 ±1.82 35.20 ±0.89
STZ-induced diabetic control
(40mg/kg) 35.46 ±0.43a,# 23.58 ±1.79a,# 9.63 ±0.67a,# 28.45 ±1.48a,# 12.31 ±0.63a,#
STZ + Ethyl acetate fraction
(200mg/kg) 14.37 ±0.56b,∗∗ 44.38 ±1.24b,∗∗ 20.31 ±0.42b,∗∗ 51.72 ±1.26b,∗∗ 29.84 ±0.49b,∗
STZ + Glibenclamide
(0.5mg/kg) 22.24 ±0.62 37.56 ±1.36 16.46 ±0.67 43.21 ±1.42 24.42 ±1.40b,∗
Values are mean ± SEM, 6 rats in each group,
a,#P<0.001 as compared to normal control group,
b,∗P<0.05, ∗∗P<0.001, when compared with STZ-treated control group.
Figure 1: Pancreatic section of normal rat stained with haemo-
toxylin and eosin.
Figure 2: Pancreatic section of STZ-intoxicated rat stained with
haemotoxylin and eosin.
by a reduction in number and size of islets. Figures 3 and
4, treatment with ethyl acetate fraction and glibenclamide,
show maximum cellular regeneration of pancreatic β-cells
with well-granulated and an increased number of islets.
5. Discussion
The present study was undertaken to ﬁnd out the potent
antihyperglycemic fraction from ethanol extract of Stere-
ospermum suaveolens (EESS). Diabetes mellitus aﬀects both
glucose and lipid metabolism [23]. In diabetes, the increased
Figure 3: Pancreatic section of ethyl acetate fraction + STZ-treated
rat stained with haemotoxylin and eosin.
Figure 4: Pancreatic section of Glibenclamide + STZ-treated rat
stained with haemotoxylin and eosin.
blood sugar levels might be due to either insulin resistance
of the body cells or decreased secretion of insulin from
β-cells manifested in the decreased serum insulin levels.
The fundamental mechanism underlying hyperglycemia in
diabetes mellitus involves the overproduction of glucose
by excessive hepatic glycogenolysis and gluconeogenesis,
decreased hepatic glycogenesis and, or decreased utilization
of glucose by the tissue [24].
Experimental diabetes mellitus was induced by injecting
STZ, which is probably due to the destruction of β-cells6 The Scientiﬁc World Journal
of islets of langerhans [25, 26] of pancreas leading to
high levels of blood glucose in rats. As a preliminary
antihyperglycermic activity assessment as well as to isolate
a potent fraction, the various fractions of EESS were
administrated to STZ-induced diabetic rats at a single dose
level (200mg/kg) to determine the acute eﬀect on blood
glucose concentration. Consequently, the pet ether and
ethyl acetate fractions showed signiﬁcant antihyperglycemic
activity in STZ-induced diabetic rats, while no remarkable
eﬀect on blood glucose level was observed on the rats
treated with chloroform and aqueous fractions. However, in
comparison to pet ether fraction, ethyl acetate fraction has
shown potential activity in decreasing the blood glucose level
in STZ-induced diabetic rats.
In subacute study, daily administration of ethyl acetate
fraction of EESS for 14 days signiﬁcantly decreased the
blood glucose levels in STZ-induced diabetic rats, when
compared to the diabetic control rats. This data support
our previous investigation [12] in STZ diabetic rats where
EESS signiﬁcantly reduced fasting blood glucose at the end
of 14-day period. The possible mechanism of the ethyl
acetate fraction for its antihyperglycemic eﬀect may be
through potentiation of pancreatic secretion of insulin from
remaining β-cells of islets and/or regenerated β-cells or due
to enhanced transport of blood glucose to the peripheral
tissues and/or the reduction of hepatic gluconeogenesis and
glycogenolysis, and increased hepatic glyconeogenesis. The
histopathological studies of pancreas also show that the ethyl
acetate fraction of EESS regenerates the β-cells. This ﬁnding
suggests that the antihyperglycemic activity of ethyl acetate
fraction of EESS may be due to potentiation of insulin
secretion by regeneration of β-cells.
STZ-induced diabetes is characterized by severe loss
in body weight. This may be due to increased muscle
wasting and due to loss of tissue proteins [27]. In this
study, a signiﬁcant weight loss was observed in the STZ-
induced diabetic control rats. The ethyl acetate fraction
treated rats showed signiﬁcant recovery in body weight gain
when compared to diabetic control rats. This may be due
to controlling muscle wasting and improvement in insulin
secretion as well as glycemic control by the ethyl acetate
fraction.
Glycogen is the primary intracellular storage form of
glucose and its levels in various tissues especially liver and
skeletal muscle are a direct reﬂection of insulin activity
as insulin promotes intracellular glycogen deposition by
stimulating glycogen synthase and inhibiting glycogen phos-
phorylase [28, 29] .T h ed e c r e a s ei ng l y c o g e nc o n t e n to f
liver in STZ-induced diabetic rats observed in the present
study is probably due to the lack of or resistance to insulin,
which is essential to stimulate glycogenesis and/or inhibit
glycogenolysis [30, 31]. The signiﬁcant increase of liver
glycogen levels in the ethyl acetate fraction treated rats may
beduetostimulationofglyconeogenesisand/orinhibitionof
glycogenolysis in liver.
Oxidative stress, a key pathogenic factor in the devel-
opment of diabetic complications, induces the production
of highly reactive oxygen species that are toxic to the cell
membrane in which these radicals interact with the lipid
bilayer and produce lipid peroxides [32–34].
The TBARS levels were measured in pancreas and its
levels found to be signiﬁcantly (P<0.001) increased in
diabetic control rats. In the present study, TBARS levels in
pancreasweresigniﬁcantlylowerintheethylacetatefractions
treated rats compared to the diabetic control group. This
suggests that ethyl acetate fraction of EESS may protect the
pancreas tissues from lipid peroxidation.
GSH is the major endogenous antioxidant that counters
balance free-radical-mediated damage in diabetes mellitus
[35]. It is well known that GSH is involved in the protection
of normal cell structure and function by maintaining
the redox homeostasis, quenching of free radicals and by
participatingindetoxiﬁcationreactions.TheGSHlevelswere
signiﬁcantly (P<0.001) decreased in pancreas of STZ-
induced diabetic rats. The decrease in GSH levels represents
increased utilization due to oxidative stress induced by
STZ [36]. The increased GSH content in pancreas of the
rats treated with ethyl acetate fraction of EESS may be a
factorresponsibleforinhibitionoflipidperoxidation.Hence,
the elevated level of GSH protects cellular proteins against
oxidation through glutathione redox cycle and also directly
detoxiﬁes reactive oxygen species generated from exposure
to STZ [37].
The present study also revealed that SOD and CAT
levels were decreased in pancreas in diabetic rats. SOD is an
important defense enzyme, which catalyses the dismutation
of superoxide radicals. CAT is a hemeprotein that catalyses
the reduction of hydrogen peroxides and protects the tissues
fromhighlyreactivehydroxylradicals[38].Therefore,reduc-
tion in the activity of these enzymes (SOD, CAT) may result
in a number of deleterious eﬀects due to the accumulation
of superoxide anion radicals and hydrogen peroxide [39].
These antioxidant enzymes SOD and CAT levels signiﬁcantly
increased after the treatment of ethyl acetate fraction of
EESS in STZ-induced diabetic rats indicating the free radical
scavenging activity and their protective eﬀect against cellular
damage. Antioxidants may have a role in the prevention of
diabetes.Theabovein vivo antioxidant status revealssupport
to antidiabetic eﬀect of ethyl acetate fractions.
6. Conclusion
The present research clearly indicates that the ethyl acetate
fraction of ethanol extract of Stereospermum suaveolens
exhibits antihyperglycemic in addition to antioxidant eﬀects
in STZ-induced diabetic rats, thereby justifying its eth-
nomedicinal use. Further chemical and pharmacological
investigations are in progress to elucidate in detail the active
principles and mechanism of action of ethyl acetate fraction
of EESS.
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